Loading…
Based on limited metadata, the FDA issued a Warning Letter to Medlife Pharmacy and Compounding, Inc., a pharmacy compounding operation, on April 24, 2020. While the specific violation details are not available in this metadata summary, the letter addresses concerns related to drug manufacturing or compounding practices. The warning falls under FDA's drug product oversight authority, though the specific issuing office is not identified in the available information.